Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of LY3410738 in IDH1/2-Mutant Advanced Solid Tumors
NCT04521686Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 1, open-label trial of crelosidenib in cholangiocarcinoma (CCA), chondrosarcoma, glioma and 1 more (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Recommended Phase 2 Dose up to 24 months. Started Oct 2020; status: active, not recruiting.
02
Drugs
crelosidenib
03
Conditions
cholangiocarcinoma (CCA)chondrosarcomagliomasolid tumor
Beyond the preview
Go deeper on NCT04521686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521686.